Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: Insights from EuroTR
- PMID: 40678992
- DOI: 10.1002/ejhf.3757
Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: Insights from EuroTR
Abstract
Aims: To assess the prevalence, prognostic significance, and predictors of heart failure hospitalization (HFH) before and after tricuspid transcatheter edge-to-edge repair (T-TEER) in a large real-world cohort of patients with tricuspid regurgitation (TR).
Methods and results: Data from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) were analysed. Among 1000 patients undergoing T-TEER for symptomatic TR, 361 (36.1%) had no HFH, 459 (45.9%) had one single HFH, and 180 (18.0%) had multiple HFH the year before T-TEER. Patients with any HFH had more severe heart failure compared with those without. Procedural success (residual TR ≤2) did not differ between patients with single, multiple, or no HFHs before T-TEER. Multivariable analysis showed that a history of HFH was associated with an increased mortality risk (adjusted hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.11-2.06 for single vs. no HFH; adjusted HR 1.63, 95% CI 1.15-2.31 for multiple vs. no HFH), and a higher risk of the combined endpoint of all-cause mortality or HFH. HFH risk decreased by 72% in the 1 year following T-TEER compared to the previous year. Procedural success was the sole independent predictor for reducing HFHs.
Conclusions: In the EuroTR cohort, a history of HFH was highly prevalent and associated with worse clinical outcomes. Among high-risk patients with symptomatic TR, T-TEER significantly lowered HFH risk, with residual TR grade ≤2 being the key predictor for reduced HFH incidence.
Keywords: Heart failure hospitalization; Mortality; Transcatheter edge‐to‐edge repair; Tricuspid regurgitation; T‐TEER.
© 2025 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
References
-
- Metra M, Tomasoni D, Adamo M, Bayes‐Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: Definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2023;25:776–791. https://doi.org/10.1002/ejhf.2874
-
- Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes‐Genis A, Abdelhamid M, et al. Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail 2023;25:1115–1131. https://doi.org/10.1002/EJHF.2888
-
- Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al.; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482–1487. https://doi.org/10.1161/CIRCULATIONAHA.107.696906
-
- Labrosciano C, Horton D, Air T, Tavella R, Beltrame JF, Zeitz CJ, et al. Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand. Eur J Heart Fail 2021;23:31–40. https://doi.org/10.1002/ejhf.2030
-
- Hariharaputhiran S, Peng Y, Ngo L, Ali A, Hossain S, Visvanathan R, et al. Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand. Eur J Heart Fail 2022;24:1519–1528. https://doi.org/10.1002/ejhf.2595
LinkOut - more resources
Full Text Sources